Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 30 December 2011 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) on Friday amended regulations classifying ovarian adnexal mass assessment score tests (OAMAST) systems to include a black box warning restriction that must appear in all advertising, promotion and labeling materials.
The OAMAST system is used to assess the likelihood that an adnexal pelvic mass is malignant by measuring the presence of certain proteins in serum or plasma. The device is not intended to be used as a screening or diagnostic tool for ovarian cancer.
The FDA determined that off-label use could lead to "a high frequency of unnecessary further testing and surgery due to false positive results, or to delay in tumor diagnosis due to false negative results."
The black box warning is aimed at combating those risks by providing clear warnings for indication for use and contraindications for use.
The black box warning falls under a Class II special control.
Tags: APL, Ovarian Adnexal Mass Assessment Score Test System, OAMAST, Class II, Black Box Warning, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.